| Literature DB >> 34787450 |
Deena Jalal1, Mariam G Elzayat1, Aya A Diab1, Hend E El-Shqanqery1, Omar Samir1, Usama Bakry1, Reem Hassan2,3, Mervat Elanany2,4, Lobna Shalaby5,6, Ahmed A Sayed1,7.
Abstract
Infection by multidrug-resistant (MDR) Acinetobacter baumannii is one of the major causes of hospital-acquired infections worldwide. The ability of A. baumannii to survive in adverse conditions as well as its extensive antimicrobial resistance make it one of the most difficult to treat pathogens associated with high mortality rates. The aim of this study was to investigate MDR A. baumannii that has spread among pediatric cancer patients in the Children's Cancer Hospital Egypt 57357. Whole-genome sequencing was used to characterize 31 MDR A. baumannii clinical isolates. Phenotypically, the isolates were MDR, with four isolates showing resistance to the last-resort antibiotic colistin. Multilocus sequence typing showed the presence of eight clonal groups, two of which were previously reported to cause outbreaks in Egypt, and one novel sequence type (ST), Oxf-ST2246. Identification of the circulating plasmids showed the presence of two plasmid lineages in the isolates, strongly governed by sequence type. A large number of antimicrobial genes with a range of resistance mechanisms were detected in the isolates, including β-lactamases and antibiotic efflux pumps. Analysis of insertion sequences (ISs) revealed the presence of ISAba1 and ISAba125 in all the samples, which amplify β-lactamase expression, causing extensive carbapenem resistance. Mutation analysis was used to decipher underlying mutations responsible for colistin resistance and revealed novel mutations in several outer membrane proteins, in addition to previously reported mutations in pmrB. Altogether, understanding the transmissibility of A. baumannii as well as its resistance and virulence mechanisms will help develop novel treatment options for better management of hospital-acquired infections. IMPORTANCE Acinetobacter baumannii represents a major health threat, in particular among immunocompromised cancer patients. The rise in carbapenem-resistant A. baumannii, and the development of resistance to the last-resort antimicrobial agent colistin, complicates the management of A. baumannii outbreaks and increases mortality rates. Here, we investigate 31 multidrug resistant A. baumannii isolates from pediatric cancer patients in Children's Cancer Hospital Egypt (CCHE) 57357 via whole-genome sequencing. Multilocus sequence typing (MLST) showed the presence of eight clonal groups including a novel sequence type. In silico detection of antimicrobial-resistant genes and virulence factors revealed a strong correlation between certain virulence genes and mortality as well as several point mutations in outer membrane proteins contributing to colistin resistance. Detection of CRISPR/Cas sequences in the majority of the samples was strongly correlated with the presence of prophage sequences and associated with failure of bacteriophage therapy. Altogether, understanding the genetic makeup of circulating A. baumannii is essential for better management of outbreaks.Entities:
Keywords: Acinetobacter baumannii; antimicrobial resistance genes; whole-genome sequencing
Mesh:
Substances:
Year: 2021 PMID: 34787450 PMCID: PMC8597740 DOI: 10.1128/mSphere.00725-21
Source DB: PubMed Journal: mSphere ISSN: 2379-5042 Impact factor: 4.389
FIG 1Phylogenetic tree and demographic data. Merged reads were mapped to the A. baumannii reference (GenBank accession number NZ_CP009257.1) to create a phylogenetic tree. The similarity distance between the isolates was analyzed based on SNP analysis and appended to a table showing the clinical data of the patients, and the sequence type of the isolated A. baumannii is appended. Recovery, + for negative cultures after treatment, – for persistent positive cultures until death of patient; BAL, bronchioalveolar lavage; CVP, central venous port. Isolates are color-shaded based on Pasteur ST.
FIG 2Heat map showing the presence or absence of each plasmid in each sample. Dark blue shows the presence of the plasmid, while light blue indicates its absence.
FIG 3Complex heat maps showing the presence or absence of each antibiotic resistance gene and antibiotic resistance drug class and the observed antibiotic susceptibility. The antibiotic resistance genes detected are shown in blue; dark blue shows the presence of the antibiotic resistance gene, while light blue indicates its absence. The antibiotic classes for which the detected genes confer resistance are shown in purple; dark purple shows expected resistance to a drug class, while light purple shows susceptibility. The phenotypic antibiotic resistance based on AST is shown in maroon; dark maroon shows resistance to the antibiotic, while light maroon shows susceptibility.
FIG 4Heat map showing the presence or absence of each IS. Dark blue shows the presence of the IS, while light blue indicates its absence.
FIG 5Stacked bar graph showing the resistance mechanisms represented in each isolate. After grouping of the antibiotic resistance genes by mechanism. Each color represents a mechanism of resistance; red, antibiotic efflux; blue, antibiotic inactivation; green, antibiotic target alteration; purple, antibiotic target protection; orange, antibiotic target replacement.
Virulence factors in each isolate
| Virulence mechanism | Virulence gene | Pasteur ST [no. of isolates (%)] | All isolates | |||||
|---|---|---|---|---|---|---|---|---|
| ST1 | ST2 | ST600 | ST570 | ST113 | ||||
| Adherence |
| 17/17 (100) | 7/7 (100) | 2/2 (100) | 1/1 (100) | 4/4 (100) | 31/31 (100) | |
| Biofilm formation | ||||||||
| Efflux pump | 17/17 (100) | 7/7 (100) | 2/2 (100) | 1/1 (100) | 4/4 (100) | 31/31 (100) | ||
| Biofilm-associated protein |
| 0/17 (0) | 7/7 (100) | 2/2 (100) | 1/1 (100) | 1/4 (25) | 21/31 (67.7) | |
| Csu fimbrae | 17/17 (100) | 7/7 (100) | 2/2 (100) | 1/1 (100) | 4/4 (100) | 31/31 (100%) | ||
| Biofilm formation | 17/17 (100) | 7/7 (100) | 2/2 (100) | 1/1 (100) | 4/4 (100) | 31/31 (100%) | ||
| Phospholipase | 17/17 (100) | 7/7 (100) | 2/2 (100) | 1/1 (100) | 4/4 (100) | 31/31 (100%) | ||
| Acinetobactin production | 17/17 (100) | 7/7 (100) | 2/2 (100) | 1/1 (100) | 4/4 (100) | 31/31 (100) | ||
|
| 0/17 (0) | 7/7 (100) | 2/2 (100) | 1/1 (100) | 1/4 (25) | 21/31 (67.7) | ||
| 17/17 (100) | 7/7 (100) | 2/2 (100) | 1/1 (100) | 4/4 (100) | 31/31 (100) | |||
| Regulation | ||||||||
| Quorum sensing | 17/17 (100) | 7/7 (100) | 2/2 (100) | 1/1 (100) | 4/4 (100) | 31/31 (100) | ||
| Two-component system | 17/17 (100) | 7/7 (100) | 2/2 (100) | 1/1 (100) | 4/4 (100) | 31/31 (100s) | ||
Number of recovered patients with bacteremia
| No. of recovered patients with bacteremia | ||
|---|---|---|
| Present (%) | Absent (%) | |
| 0/8 (0) | 5/17 (29.4) | |
| ColR | 0/4 (0) | 5/21 (23.8) |
FIG 6Heat map showing the prophage and CRISPR/Cas sequence distribution among isolates.
Unique mutations in colistin-resistant strains compared to colistin-susceptible strains
| Protein mutation/name | GenBank protein accession no. | Mutations in colistin-resistant strains | |||
|---|---|---|---|---|---|
| A1712 | A1816 | A1820 | A1828 | ||
| DNA-binding response regulator PmrA |
| L20F ( | M12I ( | ||
| Outer membrane proteins | |||||
| Outer membrane beta-barrel protein, OmpW family |
| L81F, N82D | L81F, N82D | ||
| OmpA family protein |
| E146fs | |||
| Outer membrane porin, OprD family |
| P86T | |||
| TonB-dependent receptor |
| V443A | |||
| Pilin pilA |
| A29Q | |||
| LPS export ABC transporter permease LptF ( |
| R30H | |||
| ABC transporter permease |
| H196Y | A41V | ||
| Multidrug efflux MFS transporter AmvA |
| Q294L | |||
| LysE family translocator |
| G109D | A108L, G109D | A108L, G109D | |
| DMT family transporter |
| V293fs | |||
STOP codon inserted. fs, frameshift.
FIG 7Bioinformatics workflow. The workflow shows the bioinformatics pipeline used to analyze the whole-genome sequencing data generated from Illumina MiSeqDx.